Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. - Wikidata - awgldk - TriplyDB

Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia.

Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia.

http://www.wikidata.org/entity/Q34784166

about

RING finger protein RNF207, a novel regulator of cardiac excitation Pharmacogenomics discovery and implementation in genome-wide association studies era hERG channel function: beyond long QT Pharmacogenomics of adverse drug reactions Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy Drug- and non-drug-associated QT interval prolongation.New atypical antipsychotics for schizophrenia: iloperidone Pharmacogenetics and personal genomes.SLCO3A1, A novel crohn's disease-associated gene, regulates nf-κB activity and associates with intestinal perforation Genome-wide association studies in pharmacogenomics: successes and lessons.Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction Integrative computational and experimental approaches to establish a post-myocardial infarction knowledge map.The promise and reality of pharmacogenetics in psychiatry Genome-wide association study of antipsychotic-induced QTc interval prolongation.Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes.A proximity-based method to identify genomic regions correlated with a continuously varying environmental variable.Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.Pharmacogenetics of Potassium Channel Blockers.Genetics can contribute to the prognosis of Brugada syndrome: a pilot model for risk stratification.Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval.Genome-wide association studies in pharmacogenomics: untapped potential for translation Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study.Long-term efficacy and safety of iloperidone: an update.Comparison of study designs used to detect and characterize pharmacogenomic interactions in nonexperimental studies: a simulation study.Iloperidone: a new option for the treatment of schizophrenia.Advances in molecular genetics of panic disorder.Iloperidone for the treatment of schizophrenia.Iloperidone for schizophrenia.Pharmacogenomics of antipsychotics efficacy for schizophrenia.Pharmacogenetics of response to antipsychotics in patients with schizophrenia.Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia.Integrative genomics strategies to elucidate the complexity of drug response.Pharmacological and clinical profile of recently approved second-generation antipsychotics: implications for treatment of schizophrenia in older patients.Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study.Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.Genetics of congenital and drug-induced long QT syndromes: current evidence and future research perspectives.Newer antipsychotics and upcoming molecules for schizophrenia.Safety profile of iloperidone in the treatment of schizophrenia.Pharmacogenetics of second-generation antipsychotics.

P2860

Q24305127-8590D632-2E08-4286-B1D6-E425C986809E Q27001573-7B750647-F1EB-4AA6-BABE-03373A9BB10D Q27008078-8D881253-8E9F-4621-8558-1E60DB892758 Q27015820-00231DFB-9082-417F-927C-43ADFF4BDA94 Q28078158-AC396337-27DF-4346-8432-D4DA939C4B70 Q30474909-F3F673B3-5AAC-408A-AFB3-33B23D3579B9 Q30482195-C5BA39A4-5C2F-4437-9626-54B11E2674BE Q33679969-8183EB8B-BADF-4680-8745-07D5B4024B4E Q33779677-68BCD55A-500D-4147-B470-81DD546D1505 Q34415006-C01D34EB-C1B3-44F1-9915-EE8D59BCE245 Q34676533-FF74EDDF-AC86-40D9-A15F-6158D5F966C0 Q35126269-B89CA3CD-11DC-41B2-80F6-C572A1CD1FE1 Q35226451-6A5EF22A-7EBE-42AE-A69D-FE4E345B9DEF Q36073692-D0F4132E-BDEE-4F95-A60F-398FE80E9A8E Q36084069-7D223980-FDC9-43B3-A4F2-8825EFA8379E Q36173814-7D8F1F39-7C37-408F-90D0-A53E690B0E75 Q36590631-87FF4B94-C7DF-4135-8E16-69623C6B4776 Q36702588-F0A6D93E-4891-42F9-94E1-BA04C1ABAE98 Q36970927-E6D9E771-A6DF-483A-A877-563C9DA51905 Q37102131-BC480604-0F1C-426A-8E86-4B9D2D5AD56A Q37154348-AD712DF1-2D53-4B95-B0AD-C7CC18A724CC Q37198455-38734E39-D886-4B0F-8880-0C3257F7481F Q37353278-D6EA790D-0499-4627-8D7D-4DF98E1B68B6 Q37616980-ECD4AF2D-29F4-43D6-82CA-33CAFABD9D37 Q37624739-11F38E5B-DC4D-4FF8-BD1D-D4E90EF1E330 Q37641995-476F423C-8BD7-488C-A30D-E220EE093467 Q37667843-55E7C048-75B7-45F8-B0FF-14DA7315262D Q37730307-74EAE9F4-E57C-4D1C-B034-D1F099303EBC Q37768462-2054E6D9-80B1-4BA8-B096-C848F52F78D1 Q37832287-22FCDCF6-91BC-40BB-B819-26E2D0ACE765 Q37952823-4E9B13DD-D0E6-48CA-8778-FE3633DD2E76 Q37960512-E6F46AB5-7BAC-4B6A-A78B-BD6BB16AB56F Q37961088-5EA38F07-C28F-4765-9A3D-8FF1B3FBD373 Q38047222-940EE447-35C4-4DBF-9E4D-2EB05353AF6A Q38061501-E770A672-C7A3-4A83-B6CE-AE7957B8D9B9 Q38070179-8CB2C0F7-931E-4971-88F1-265EB24C7DE1 Q38091648-EDC5BE34-C0A1-4552-BA95-8FCFE3C384D9 Q38094930-55FFD50C-DE58-4B32-8CEF-E09DFEC5304F Q38160942-B0A2EC95-ADDF-4218-8FFE-DB293545F717 Q38217628-5D9D564C-6AC6-4A9F-99AB-25E07B211C20

P2860

Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia.

http://www.wikidata.org/entity/Q34784166

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Whole genome association study ...... ne treatment of schizophrenia.

@ast

Whole genome association study ...... ne treatment of schizophrenia.

@en

Whole genome association study ...... ne treatment of schizophrenia.

@nl

type

label

Whole genome association study ...... ne treatment of schizophrenia.

@ast

Whole genome association study ...... ne treatment of schizophrenia.

@en

Whole genome association study ...... ne treatment of schizophrenia.

@nl

prefLabel

Whole genome association study ...... ne treatment of schizophrenia.

@ast

Whole genome association study ...... ne treatment of schizophrenia.

@en

Whole genome association study ...... ne treatment of schizophrenia.

@nl

P1433

Q34784166-5316FE0B-BE0E-4A49-BF3E-E3AB43582DA7

P1476

Q34784166-CC639702-E9DB-4F6B-87E3-CFFE9098E3E6

P2093

Q34784166-6560F601-0139-423C-9F8D-5AA2098D5931

Q34784166-68BC9BC6-D72B-44DC-B02B-FEA94E8BE699

Q34784166-6EA50B90-940C-4FBB-A450-4D1D29F9EB83

Q34784166-7276DC68-E4E9-4915-8C3F-8444AE0809E4

Q34784166-87A5083D-D9A9-4DA8-A63B-531C27606126

Q34784166-A5E11363-CD88-4C5B-BE78-02406FDA0F92

Q34784166-B1578824-5B4E-4054-AB88-6B0507AF8B48

Q34784166-B953E858-BF6C-474C-A0F5-35B7F27B1C92

Q34784166-D6316766-EF75-4172-AA59-88E7C2AA75C8

P2860

Q34784166-04E699F3-E21D-47A5-B314-06D02F69735D

Q34784166-05EC2320-AAA8-45ED-9B99-312C2EF8B25F

Q34784166-110F4F70-C6CE-42D1-8441-C4CC32319FBF

Q34784166-1745A0B9-46DA-4153-AF27-527AE268F255

Q34784166-1C43AF5A-E7B5-4690-84B1-EA405843BB55

Q34784166-1F39F587-5ADD-4E7B-93D2-620273A296D3

Q34784166-22C2AD1A-BEFA-45FF-B92B-23F287FA75C8

Q34784166-26753E2A-B2DA-4479-94D2-9BC459C40384

Q34784166-2E65B96E-D946-4F85-81B1-C6E5DBB30D3E

Q34784166-55201BC6-855C-4FF3-8C86-71835F9BD2D9

P2888

Q34784166-5867FE30-090D-49DE-BAB7-32D88F3008F3

P304

Q34784166-B67593F8-F0EC-49C3-88A5-2F14BDC7E34A

P31

Q34784166-FD53F29D-53D6-4A6F-9C0E-F5C44E4B6F0F

P356

Q34784166-314CFE77-DDB1-45AA-B8FD-878E323DC914

P407

Q34784166-B1225964-6D5A-4850-A97F-8F267076062B

P433

Q34784166-353EA07A-33D2-439D-AA15-DC66239C8222

P478

Q34784166-5EBD8FB4-A893-4724-B245-2D689212FFBA

P577

Q34784166-2F58D13B-B6A8-40B6-9CB1-8EF8D978775C

P5875

Q34784166-EAB89F27-9DD7-4733-AA64-CFF909C11965

P6179

Q34784166-9344EA73-E81F-4D82-988A-883D0A92E49E

P698

Q34784166-C1968CB7-13B1-41EA-BADC-6F474FF169C5

P921

Q34784166-18A64F8B-29F5-45E2-B47D-309903A8A9D7

P356

P1433

Molecular Psychiatry

P1476

Whole genome association study ...... ne treatment of schizophrenia.

@en

P2093

C D Wolfgang

http://www.w3.org/2001/XMLSchema#string

C Heaton

http://www.w3.org/2001/XMLSchema#string

C Lavedan

http://www.w3.org/2001/XMLSchema#string

J B Hamilton

http://www.w3.org/2001/XMLSchema#string

K Mack

http://www.w3.org/2001/XMLSchema#string

L Licamele

http://www.w3.org/2001/XMLSchema#string

M H Polymeropoulos

http://www.w3.org/2001/XMLSchema#string

R Lannan

http://www.w3.org/2001/XMLSchema#string

S Volpi

http://www.w3.org/2001/XMLSchema#string

P2860

Cardiac elav-type RNA-binding protein (ETR-3) binds to RNA CUG repeats expanded in myotonic dystrophy

The CELF family of RNA binding proteins is implicated in cell-specific and developmentally regulated alternative splicing

Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes

Identification of four gene variants associated with myocardial infarction.

dbSNP: the NCBI database of genetic variation

Neuregulin3 alters cell fate in the epidermis and mammary gland

Haploview: analysis and visualization of LD and haplotype maps

Genomic organization and isoform-specific tissue expression of human NAPOR (CUGBP2) as a candidate gene for familial arrhythmogenic right ventricular dysplasia

Dynamic balance between activation and repression regulates pre-mRNA alternative splicing during heart development

Angiotensin II, focal adhesion kinase, and PRX1 enhance smooth muscle expression of lipoma preferred partner and its newly identified binding partner palladin to promote cell migration.

P2888

P304

1024-1031

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MP.2008.52

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51397569

http://www.w3.org/2001/XMLSchema#string

P6179

1046235988

http://www.w3.org/2001/XMLSchema#string

P698

18521091

http://www.w3.org/2001/XMLSchema#string

P921